Biodexa Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent Glioblastoma
October 4, 2024 Biodexa Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent Glioblastoma Cohort A Data on Overall Survival Compare Favorably with Published Survival Rates Results Build on MTX110’s Performance in …